Loading patent…
AssigneeHoffmann-La Roche Inc.
InventorsMichael Bös, Heinz Stadler, Jürgen Wichmann
Estimating the term…
Since the compounds in accordance with the invention can bind to serotonin receptors (5HT2), they are especially suitable for the treatment or prevention of central nervous disorders such as depressions, bipolar disorders, anxiety states, sleep and sexual disorders, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or pain of a different kind, personality disorders or obsessive-compulsive disorders, social phobias or panic attacks, mental organic disorders, mental disorders in childhood, aggressivity, age-related memory disorders and behavioral disorders, addiction, obesity, bulimia etc., nervous system damage caused by trauma, stroke, neurodegenerative diseases etc.; cardiovascular disorders such as hypertension, thrombosis, stroke etc.; and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
A compound of the formula
A compound, cis-2-Methyl-1,3,4,4a,5,11b-hexahydro-2H-8,10-dioxa-2-aza-cyclopenta[b]phenanthren-6-one.
A compound, rac-cis-8-fluoro-2-propyl-1,3,4,4a,5,10b-hexahydro-2H-benzo[h]isoquinolin-6-one, or the pharmaceutically acceptable salts thereof.
A compound, rac-cis-8-fluoro-2-ethyl-1,3,4,4a,5,10b-hexahydro-2H-benzo[h]isoquinolin-6-one, or the pharmaceutically acceptable salts thereof.
A compound, rac-cis-2-benzyl-8-fluoro-1,3,4,4a,5,10b-hexahydro-2H-benzo[h]isoquinolin-6-one, or the pharmaceutically acceptable salts thereof.
A compound, rac-(+)-7,9-dimethyl-2-propyl-1,3,4,4a,5,10b-hexahydro-2H-benzo[h]isoquinolin-6-one or the pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.